(688319)"Chengdu Olymvax Biopharmaceuticals Inc."Report for Q3 2026
Filed with SSE · Stock code 688319 · · 12 pages · Chinese
Summary by 6ix AI
The report indicates a decline in net profit attributable to shareholders compared to the previous year, alongside a decrease in total profit. The company also reported a significant drop in earnings per share and a reduction in research and development expenditures as a percentage of revenue. Total assets increased slightly, while total liabilities also rose, reflecting ongoing financial challenges.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Chengdu Olymvax Biopharmaceuticals Inc. on 6ix
Earlier from Chengdu Olymvax Biopharmaceuticals
- (688319)"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Voluntary Disclosure of Receipt of the Phase III Clinical Study Summary Report for the Recombinant Staphylococcus aureus Vaccine (E. coli)
- (688319)"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Progress of Litigation
- Announcement on Shareholding Reduction Plan of a Director and Senior Management Member
- Niutech Signs Agreement with Global Energy Major for Waste Plastic Pyrolysis Line to Produce SAF
- Semi-annual Report for 2026
Later from Chengdu Olymvax Biopharmaceuticals
- (688319)"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Release of Pledge of Certain Shares Held by Shareholder Holding More Than 5% of the Shares
- (688319)"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Convening the Q3 2026 Performance Briefing
- (688319)"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Pledge of Certain Shares Held by Shareholders Holding More Than 5% of the Shares
Follow Chengdu Olymvax Biopharmaceuticals into a list and get an email when it puts out news.
Follow Chengdu Olymvax Biopharmaceuticals